Immune checkpoint blockade (ICB) therapy, such as with antibodies against programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), has shown promising effectiveness in patients with ccRCC [2]. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.